Harry E. Gruber

HARRY E. GRUBER, M.D. has a strong capacity to be a major contributor to
frontiers of new technologies. In 1980, Dr. Gruber co-founded, initially
financed, and wrote the initial patents for Gensia. Gensia, one of the
first functional genomics companies, was also the first San Diego
biotech company to reach a billion dollar market cap. In 1987, Dr.
Gruber founded, financed, and wrote the patents for Viagene, the first
gene therapy company. The field of gene therapy has since exploded, and
Viagene was purchased by Chiron for $150 million shortly after going
public. Dr. Gruber provided the intellectual property for Aramed, a
third publicly traded company. Aramed reached a market cap in excess of
$500 million, and was repurchased by Gensia. In 1994, Dr. Gruber
licensed patents in tumor vascular biology from UCSD and Harvard to help
form a fourth company, Vascular Genomics. Without the participation of
any investors, Corvas entered into a strategic alliance with an option
to buy Vascular Genomics for approximately $20 million. Dr. Gruber is
currently co-founder and Chief Executive Officer of InterVU, Inc.
founded in August 1995. The company has pioneered the delivery of video
and multimedia over the Internet. Dr. Gruber co-invented the company’s
technology with Brian Kenner.